In the rush to develop effective vaccines against the novel coronavirus, several companies have sued, and counter-sued, for patent infringement, with potentially billions on the line.
Leading mRNA vaccine developers Pfizer (NYSE: PFE), BioNTech (Nasdaq: BNTX) and Moderna (Nasdaq: MRNA) are all subject to litigation in multiple jurisdictions.
The latest installment in this slow-moving clash of the titans is a decision from The European Patent Office, which invalidated a patent held by Moderna, causing the American biotech’s shares to trend downwards.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze